NeuroSense Therapeutics (NASDAQ:NRSN) Coverage Initiated by Analysts at HC Wainwright

Stock analysts at HC Wainwright assumed coverage on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a note issued to investors on Thursday, Benzinga reports. The firm set a “buy” rating on the stock.

Separately, Weiss Ratings cut shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $8.50.

NeuroSense Therapeutics Stock Performance

Shares of NeuroSense Therapeutics stock opened at $0.41 on Thursday. The stock has a market cap of $15.51 million, a price-to-earnings ratio of -0.76 and a beta of 1.60. The stock has a 50 day moving average price of $0.56 and a 200-day moving average price of $0.72. NeuroSense Therapeutics has a one year low of $0.25 and a one year high of $1.98.

Insider Activity

In other news, CEO Alon Ben-Noon purchased 250,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were acquired at an average cost of $0.80 per share, with a total value of $200,000.00. Following the completion of the acquisition, the chief executive officer owned 4,534,233 shares of the company’s stock, valued at $3,627,386.40. This trade represents a 5.84% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Or Eisenberg acquired 250,000 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The shares were acquired at an average price of $0.80 per share, with a total value of $200,000.00. Following the acquisition, the chief financial officer owned 1,504,050 shares in the company, valued at approximately $1,203,240. The trade was a 19.94% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 27.40% of the company’s stock.

Institutional Trading of NeuroSense Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in NeuroSense Therapeutics during the 2nd quarter valued at approximately $54,000. Squarepoint Ops LLC increased its position in shares of NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares during the period. Two Sigma Investments LP acquired a new position in shares of NeuroSense Therapeutics in the 3rd quarter valued at $26,000. Finally, Yorkville Advisors Global LP purchased a new position in NeuroSense Therapeutics in the 4th quarter worth $77,000. 1.04% of the stock is currently owned by institutional investors and hedge funds.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.